Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation

Inclusion Criteria: * Patient must be ≥ 12 years and ≤ 60 years * Confirmed diagnosis of complicated extracranial AVMs made by a physician who is familiar with this condition. * Genetic testing for mutations within MAP2K1 or remaining RAS/MAPK pathway is preferred but not mandatory * Patient is able to swallow and/or retain oral medication via G tube * All clinical and laboratory studies to determine eligibility will be performed within six weeks prior to enrollment unless otherwise indicated. * Patients who have undergone surgical resection or interventional radiology procedures (sclerotherapy) of their AVM are eligible if they meet all inclusion criteria after these procedures * At least 4 weeks from undergoing any major surgery * Patients with endocrine deficiencies are allowed to receive physiologic or stress doses of steroids if necessary. * Myelosuppressive chemotherapy: None within 4 weeks of entry into this study. * At least 14 days since the completion of therapy with a biologic. For agents that have known adverse events occurring beyond 14 days after administration, this period must be extended beyond the time during which adverse events are known to occur. These patients must be discussed among PI and other investigators on a case-by-case basis. * Patients must not have received an investigational drug within the prior 4 weeks. * Not within 6 months prior to entering study if AVM is within field of radiation Exclusion Criteria: * AVM due to germline mutation suc…